Pathogenic Neisseria illustrates both the successes and remaining challenges of bacterial vaccinology. Neisseria meningitidis and Neisseria gonorrhoeae are genetically related, human-adapted organisms, yet cause distinct diseases: rapidly invasive, life-threatening infection for meningococcus, and predominantly mucosal, often asymptomatic infection for gonococcus. These differences reflect divergent host–pathogen interactions and immune requirements that have shaped vaccine development.
For meningococcus, conjugate, OMV-based, and genome-informed protein vaccines have delivered highly effective prevention. This success reflects alignment of antigen selection with serogroup distribution, strain epidemiology, and antigenic diversity, while serum bactericidal activity remains a key mechanistic correlate that has supported licensure without conventional efficacy trials.
In contrast, gonococcus has largely evaded vaccine development despite sharing significant genome conservation and many potential targets with meningococcus. Protective immunity remains poorly defined, natural immune memory is limited, and antigenic variation and immune modulation are extensive. Emerging evidence, including 4CMenB-associated cross-protection, is reshaping the field by linking OMV-based strategies, targeted antigen prioritization, and functional immune readouts more directly to gonococcal vaccine development, although translation remains constrained by preclinical models that incompletely recapitulate human infection and immunogenicity.
Together, these advances are reframing gonococcal vaccine development as a testable immunological problem. The current 4CMenB conundrum—moderate protection suggested by multiple real-world effectiveness studies in the general population, but no clear efficacy in randomized trials of high-risk populations with substantial prior exposure—sharpens the central question: how to define, measure, and intentionally elicit protective immunity in a mucosal infection that does not reliably generate it naturally.